Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system.
- Author:
Hui-Hui SONG
1
;
Bao-An CHEN
;
Jia-Hua DING
;
Xue-Mei SUN
;
Chong GAO
;
Yun-Yu SUN
;
Jun WANG
;
Jian CHENG
;
Gang ZHAO
Author Information
1. Department of Hemotology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Female;
Humans;
Lymphoma, Non-Hodgkin;
therapy;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
adverse effects;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
therapy;
Treatment Outcome
- From:
Journal of Experimental Hematology
2006;14(5):945-948
- CountryChina
- Language:Chinese
-
Abstract:
The study was aimed to investigate the effect of hematopoietic stem cells transplantation (HSCT) in treatment for hematologic malignancies of lymphatic system. Through observing 8 patients with non-Hodgkin's lymphoma (NHL) and 3 patients with lymphoblastic leukemia, who received auto or allo-HSCT after chemotherapy, the hematopoietic reconstitution, complication and survival time were evaluated. The results showed that 11 patients (7 patients after auto-PBSCT, 4 patients after allo-PBSCT) all achieved hematopoietic reconstitution and complete remission (CR). Within three years following-up, 5 patients with NHL were survival, but one case of NHL died at the 2 months after auto-PBSCT, one patient suicided. From 4 cases received allo-PBSCT, one patient with NHL (NK cell) was died at 79 days later, one patient with chronic lymphoblastic leukemia was surviving, another 2 cases of acute lymphoblastic leukemia were dead at 17 months and 54 days respectively after allo-PBSCT. In conclusion HSCT is an effective treatment for hematologic malignancies of lymphatic system, but the replase would occur in some patients received auto-PBSCT. The others by allo-PBSCT might die of severe complication of transplantation.
